Ulcerative Colitis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms – Claims Data Analysis Adult (US) | 2022
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs]) that are often effective for those patients with mild to moderate disease. Treatment then progresses to more-potent drugs, such as immunosuppressants and/or biologics, as needed. Among the biologics, tumor necrosis factor (TNF)-alpha inhibitors (Janssen’s Remicade and AbbVie’s Humira) and a cell adhesion molecule (CAM) inhibitor (Takeda’s Entyvio) are the mainstays of treatment. However, therapies such as Pfizer’s Xeljanz / Xeljanz XR and Janssen’s Stelara are increasing the competition in the market, among later-line targeted therapies.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult UC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult UC patients?
- How have Stelara and Entyvio been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of adult UC patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within in 365 days of diagnosis?
- What percentage of adult UC patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Markets covered: United States
Key companies: AbbVie, Janssen, Pfizer, Takeda, UCB, BMS
Key drugs: Zeposia, Entyvio, Humira, Remicade, Simponi, Stelara, Xeljanz / Xeljanz XR, aminosalicylates
Table of contents
- Ulcerative Colitis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis Adult (US) | 2022
- Treatment Algorithms CDA Ulcerative Colitis (Adult) US March 2022
- Treatment Algorithms CDA Ulcerative Colitis (Adult) US 2022 Dashboard
Ritesh Gupta, Ph.D., is a manager in the Immune and Inflammatory Disorders team at Clarivate. He has years of experience in competitive intelligence, scientific analysis, and market opportunity assessment and has worked in various therapeutic areas to provide strategic recommendations to pharmaceutical companies. He holds a Ph.D. in cell biology from the Max Delbrück Center for Molecular Medicine in Berlin.